CONTEXT AND OBJECTIVE: Acute kidney injury (AKI) is still a headache for clinicians and scientists as a possible reason for increased death among intensive care unit (ICU) patients after invasive cardiac surgery. Furthermore, the diagnostic process for AKI using conventional biomarkers is not sufficient to ensure early warning of this condition because of the morbid influence of non-renal factors that definitively delay the time for the prognosis. These imposed limitations have led to significant amounts of research targeted towards identifying novel biomarkers for AKI with a sustained degree of sensitivity and specificity. Here, we reviewed previous studies conducted on the Klotho, CYR61 and YKL-40 biomarkers in relation to AKI. DESIGN AND SETTING: Review of the literature conducted in the METHODS: The literature was searched in PubMed and the Cochrane Library. From the database of this specialty, we selected 17 references that matched our context for detailed analysis and further investigation. RESULTS: The studies reviewed showed notable differences in their results relating to the diagnostic impact of Klotho, CYR61 and YKL-40 on early prediction of AKI. CONCLUSIONS: The results regarding the Klotho, CYR61 and YKL-40 biomarkers showed markedly equivocal performance in the previous studies and did not fulfill the expectations that these factors would form valid possible biomarkers for AKI.
INTRODUCTION
Acute kidney injury (AKI) is a highly progressive critical problem that often occurs after invasive cardiac surgery using cardiopulmonary bypass (CBP). 1, 2 It threatens the life of intensive care unit (ICU) hospitalized patients through accompanying irreversible adverse outcomes that ultimately contribute to a 60% increase in mortality rate. 3 Defining AKI is dependent on measurement of baseline serum creatinine, the traditional biomarker of kidney function, which remains unchanged until a sudden 50% of kidney function is lost. 4 Moreover, AKI has been found to be strongly affected by dietary status, exercise, protein supplements, corticosteroids, age, gender and muscle mass. 5, 6 Therefore, there is an urgent need for novel biomarkers to predict and diagnose AKI at its earlier stages, so as to prevent complications and potentiate therapeutic approaches.
Classification of AKI
The Acute Dialysis Quality Initiative Group (ADQI) meeting in 2004 gave rise to a new regular criterion for analyzing kidney function, termed Risk Injury Failure Loss of function and End stage (RIFLE). 7, 8 RIFLE was dependent on serum creatinine (SCr) or urinary output (UO) measurements to determine the prognostic severity of deterioration of kidney function, classified into three stages. 8 Many studies mentioned that the usefulness of RIFLE was affected by the following substantial limitations: [1] calculation of the SCr baseline using the Modification of Diet in Renal Disease (MDRD) equation showed high specificity for chronic kidney disease (CKD) but not AKI; [2] SCr was directly influenced by nonspecific factors and hence was unreliable; [3] using UO was a good alternative for SCr, but it was affected by diuretics and could only be measured by using a bladder catheter in an ICU and not among long-stay hospitalized patients; and [4] SCr was considered to be a marker for renal function, not kidney injury. 9 Subsequently, a modified standard was published in 2007 under the name "Acute Kidney Injury Network (AKIN)", with the aim of closing gaps generated by RIFLE. AKIN used two values of SCr within two days instead of baseline SCr, regardless of glomerular filtration rate (GFR) changes. According to AKIN, stage 3 AKI was confirmed when the duration of increased SCr levels did not exceed 48 h and the patient required renal replacement therapy (RRT). 10 The failure of both RIFLE and AKIN to fulfill precise prognostic stratification of AKI severity and to provide a unified definition of AKI was the reason for establishing the Kidney Disease Improving Global Outcomes (KDIGO) guidelines. These novel criteria suggested that AKI should be defined by SCr levels that reached 26.4 μmol/l within 48 h or increased to a level 1.5 times higher than the baseline level within 7 days, which provides a sufficient timeframe for AKI diagnosis. 11 The differences between all the diagnostic criteria are summarized in Table 1 .
Epidemiology of AKI
The AKI incidence rate worldwide has remained imprecise because of the small number of case report studies, gaps in the data collected from patients and differences in definitions of AKI between developed and developing countries. [12] [13] [14] Recent studies conducted in the USA and Spain showed incidences of approximately 23.8 cases per 1000 discharges and 209 cases per million, respectively. 15, 16 A recent population-based study conducted in the UK reported high incidence of AKI, of 1811 cases per million in 2003. 17 A report from Kuwait indicated an incidence of 4.1 cases per 100,000 population per year. 18 In addition, the annual incidences for AKI in Brazil and northern India were 7.9 and 6.4 cases per 1000 admissions. 19, 20 Notably, the mortality Table 1 . Differences between the guidelines "risk injury failure loss of function and end stage" (RIFLE), "acute kidney injury network" (AKIN) and "kidney disease improving global outcomes" (KDIGO) for diagnosing acute kidney injury (AKI) rates in developed countries were found to be lower than those in developing countries, where young adults and children were very badly affected. 21
Prospective biomarkers
Klotho Klotho (KL) is a novel phosphatonin encoded by the anti-aging KL gene located on chromosome 13q12 as an inactive singlepass transmembrane protein. 22 Upon activation through action by membrane bound-secretases like ADAM10 and ADAM17, driven by insulin, the extracellular domain is cleaved and its serum, urine and cerebrospinal fluid levels become elevated. 23 This ectodomain was termed a soluble Klotho, which would possibly bind directly with FGFR and tend to form an active complex exhibiting high affinity against FGF, 24 thereby alleviating oxidative stress through suppression of growth factors and stimulation of calcium ion channels (TRPV5 and TRPV6) 23 and potassium channels (ROMK) 25 but not sodium-phosphate cotransporters. 26 Meanwhile, the remaining membrane Klotho would function as a coreceptor for bone regulatory hormone FGF23. 27 Normally, Klotho shows greater expression in distal rather than proximal convoluted tubules in the kidneys, and in the choroid plexus of the brain rather than in the heart and parathyroid gland. 28 The pathological importance of Klotho emerged through studies on animal models for AKI that had previously undergone ischemic reperfusion injury (IRI) or unilateral urethral obstruction (UUO). Thus, a transient reduction in renal Klotho mRNA expression was shown in response to renal tubular injury. 29, 30 Other studies on Klotho applied to humans have demonstrated that the urinary and plasma levels of Klotho in patients with AKI are notably lower than in healthy individuals. 29 From these observations, it has been proposed that Klotho has a role in exacerbating renal damage and has potential as a likely biomarker for AKI.
Cysteine-rich protein 61 (CYR61)
CYR61 is a cysteine-rich matricellular protein encoded by the CYR61 gene located on chromosome 1p22.3. It is intercalated with various integrins and heparin sulfate proteoglycans and is associated with extracellular matrix formation, cell adhesion, proliferation, differentiation, angiogenesis, apoptosis and inflammation due to its biochemical features, which resemble Wnt-1 proto-oncogene, and its number of growth factors. 31 Additionally, renal CYR61 mRNA and protein expression, along with urinary levels, have been found to increase in IRI animal models that suffered from significant hypoxia, despite being indistinguishable at renal levels in normal tissues. 32, 33 This result provides encouragement to study CYR61 levels in humans, in order to elucidate its preventive and/or predictive role against AKI.
Chitinase-3-like protein 1 (YKL-40)
Chitinase-3-like protein 1 (CHI3L1) or YKL-40 is a 40 kDa glycoprotein 34 that is expressed from the CHI3L1 gene located on chromosome 1q31-q32. 35 It is considered to be a member of the family of 18 glycoside hydrolases that encompasses chitinases but without any enzymatic activity. It is secreted by various cell types, including macrophages, chondrocytes and some types of cancer cells. 34 from human patients with sepsis. They showed similar quantitative increases in comparison with controls without AKI. 36 Therefore, studies on YKL-40 remain a prerequisite for understanding the pathophysiology of AKI.
OBJECTIVE
The objective of the current review was to focus on the suitability and validity of Klotho, CYR61 and YKL-40 as ideal predictive biomarkers for acute kidney injury.
METHODS
We conducted a comprehensive systematic search by using the and Acute Kidney Injury''). The search strategy was designed for the PubMed database and was altered as needed for use in other databases. Our last search was finished in January 2016.
References were written in the English language. The inclusion criterion was that all research articles, review articles and observational studies included needed to match our context, i.e. "the propensity of CYR61, Klotho and YKL-40 to be novel biomarkers for AKI". Additionally, we excluded papers that investigated these biomarkers in relation to chronic kidney disease (CKD) and other diseases as well as AKI.
RESULTS
Our search revealed a total of 2917 references. From the title and abstract, while omitting review articles, case reports and similar results, the number of papers was reduced to 17, which included seven relating to the biomarker YKL-40, three relating to CYR61 and seven relating to Klotho ( Table 2) . Briefly, we summarized the main results and recommendations for each study in Table 3 . 29, 30, 32, [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] Finally, a synopsis of the biomarkers studied, showing general descriptions, functions and techniques used for measurements, was produced as Table 4 .
DISCUSSION
In this review article, we discuss the propensity of some novel biomarkers for early detection of AKI. Traditional biomarkers have been proven to be unable to satisfactorily distinguish AKI during the first 24 hours before kidney function is disrupted. This is certain to delay the diagnostic process and gives rise to the possibility that the patient's condition will worsen. 
Number of inclusions

Number of exclusions
PubMed Klotho AND "acute kidney injury"[MeSH Terms] 31
Included in the review article Excluded because of duplication or lack of match with specialization of proposed description Cysteine rich protein 61 and "acute kidney injury" 11 Chitinase-3-like protein 1 and "acute kidney injury" 4
Scopus
Klotho and " acute kidney injury" 45 CYR61 and " acute kidney injury" 9 Chitinase-3-like protein 1 and "acute kidney injury" 5
SciELO
Klotho and AKI/"acute kidney injury" 2 CYR61 1 YKL- 40 2 Cochrane Library 37 Pilot study
To evaluate whether urinary Chitinase 3-like protein 1 (YKL-40) can predict AKI stage ≥ 2 in ICU patients compared with NGAL.
The concentration of UCHI3L1 within 12 hours of AKI stage ≥ 2 was increased with good performance on AUC-ROC curve (0.792, 95% CI), similar to UNGAL AUC-ROC (0.748, 95% CI), and after 24 h, UCHI3L1 showed AUC-ROC twice as high (95% CI: 1.3-3.1) as controls. 40 Observational cohort study
To measure YKL-40 levels in the urine of clinically hospitalized AKI patients.
Urinary YKL-40 levels were detectable (≥ 5 ng/ml) within 1 h and gave better prognostic value (P = 0.04) with NGAL. 5 Tatar et al. 41 Cohort study To define relationship between YKL-40 and proteinuria in renal transplant recipients.
Mean serum YKL-40 and proteinuria levels were 66 ± 46 ng/ ml and 0.77 ± 1.15 g/day respectively without any apparent correlation. 6 Maddens et al. 36 Clinical and experimental study Measurement of urinary and plasma levels of Chitinase 3-like protein 1 and -3 in mice and patients with and without septic AKI.
Urinary CHI3L1 higher in septic-AKI patients than in non-AKI (P < 0.05), but in septic-AKI mice models, CHI3L1 and -3 were found to be high. 7 Malyszko et al. 42 Review article
Illustration of candidate biomarkers in cases of delayed graft function as a form of acute kidney injury.
Elevated YKL-40 in both urine and serum levels of patients with DGF, 2 days after transplantation. 8 Muramatsu et al. 32 Experimental study
To test CYR61 in the urinary levels of mice and rats after immediate renal ischemic reperfusion injury.
CYR61 protein increased first within 1 h and appeared in urine 3-6 h after ischemic renal injury. 9 Lai et al. 43 Experimental study
To investigate the role of CYR61 after unilateral IRI in mice.
CYR61 was significantly induced at renal and urinary levels after IRI. 10 Xu et al. 44 Experimental study
To indicate CYR61 expression in renal cell lines under hypoxia
Enhanced expression of renal CYR61 in response to hypoxic ischemic injury.
11
Kim et al. 45 Cohort study
To determine possible influence of AKI on serum and urinary levels of Klotho, S100A8/ A9 and NGAL Urinary Klotho levels were 13.21 ± 17.32 versus 72.97 ± 17.96 pg/ml (P = 0.002) in pre-renal and intrinsic AKI respectively. 12 Torregrosa et al. 46 Cohort study Assessment of urinary Klotho levels in patients after cardiac surgery or coronary angiography.
Klotho levels did not behave as a good early biomarker of AKI. 13 Castellano et al. 47 Experimental study Renal Klotho levels were significant reduced with AKI severity. 16 Hu et al. 29 Experimental and casecontrol study
To estimate Klotho at urinary and plasma levels, investigating probable protective ability.
Urinary Klotho values (pmoles/l) were 2.52 ± 0.76 in AKI versus 20.66 ± 1.81 in non-AKI, with P < 0.01.
17
Sugiura et al. 30 Experimental study
To explain the physiological relevance of renal Klotho after IRI in rats.
Renal Klotho levels were significantly reduced in IRI rats, 24 h after ischemia. which did not show any predictive power against AKI. 37 Moreover, Tatar et al. concluded that high levels of serum YKL-40 was accompanied by increased CRP and proteinuria levels in kidney transplant recipients, thus indicating its inflammatory role. 41 Although YKL-40 showed many important benefits, the pathophysiological mechanism that leads to its expression in cases of AKI remains uncertain and validated cutoffs remain largely absent.
CONCLUSION
The results regarding the Klotho, CYR61 and YKL-40 biomarkers showed markedly equivocal performance in the previous studies and did not fulfill the expectations that these factors would form valid possible biomarkers for AKI.
